Holen Sie sich die Stockscreener-App
4.99
0.00%
0.00
Schlusskurs vom Vortag:
$4.99
Offen:
$4.99
24-Stunden-Volumen:
217.21K
Relative Volume:
0.36
Marktkapitalisierung:
$48.85M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
-6.7432
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
+0.40%
1M Leistung:
+22.00%
6M Leistung:
-28.73%
1J Leistung:
-74.26%
1-Tages-Spanne:
$4.98
$4.99
1-Wochen-Bereich:
$4.97
$4.99
52-Wochen-Spanne:
$3.20
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.99 | 48.67M | 21.73M | -91.17M | -286.43M | -0.74 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
Bluebird Beats Patent Case Over Blood Disease Therapies - Law360
Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - BioSpace
Carlyle, SK Capital Partners and bluebird bio Provide Updated Te - GuruFocus
Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions - marketscreener.com
Critical Update: bluebird bio Shareholders Must Re-tender Shares Under New $5 or $3+CVR Buyout Terms - Stock Titan
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates - MSN
bluebird bio updates terms of Carlyle, SK Capital buyout By Investing.com - Investing.com Canada
Carlyle and SK Capital boost Bluebird Bio bid, offering flexible payout terms - Private Equity Insights
Bluebird: Q1 Earnings Snapshot - New Haven Register
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Bluebird Bio (BLUE) Surges on Amended Deal with Carlyle and SK C - GuruFocus
bluebird bio, Inc. SEC 10-Q Report - TradingView
Bluebird, Private Equity Firms Look To Sweeten Buyout Deal - insights.citeline.com
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equitybluebird bio (NASDAQ:BLUE) - Benzinga
bluebird bio shares soar after amended buyout offer from Carlyle, SK Capital - Proactive financial news
Bluebird Bio Stock Skyrockets on Revamped Buyout Offer - RagingBull
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67% - Fierce Pharma
Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish - MSN
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - citybiz
Bluebird bio soars on amended deal with Carlyle, SK Capital - MSN
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agree - GuruFocus
Bluebird Bio (BLUE) Amends Deal with SK Capital for Shareholder Options | BLUE Stock News - GuruFocus
Bluebird Bio Takeover Bid: Shareholder Decision on $5 Per Share OfferNews and Statistics - IndexBox
Bluebird bio soars on amended deal with Carlyle, SK Capital (BLUE:NASDAQ) - Seeking Alpha
Bluebird Bio Amends Merger Agreement with Carlyle - TipRanks
bluebird bio updates terms of Carlyle, SK Capital buyout - Investing.com Australia
bluebird bio stock soars 50% on improved buyout offer By Investing.com - Investing.com South Africa
bluebird bio stock soars 50% on improved buyout offer - Investing.com
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement | BLUE Stock News - GuruFocus
Bluebird bio warns of potential bankruptcy as buyout faces another delay - Fierce Pharma
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P TMI Index - marketscreener.com
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P Global BMI Index - marketscreener.com
Important Information for bluebird bio Stockholders to Tender Sh - GuruFocus
Gene Therapy Market Set for Strong Growth with Ongoing Rare - openPR.com
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Yahoo Finance
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
17.27%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):